Nick Smalley elected Vice Chair of IPAC-RS Board of Directors

Kindeva is pleased to announce that Nick Smalley, Vice President of Regulatory Affairs, has been elected Vice Chair of the Board of Directors for the International Pharmaceutical Aerosol Consortium on Regulation & Science (IPAC-RS). He will serve a two-year term as Vice Chair before assuming the role of Chair for a further two years. 

Nick has more than 30 years of experience across pharmaceutical development and global regulatory affairs, including leadership roles spanning inhaled medicines, consumer healthcare and prescription pharmaceuticals.  His election as Vice Chair comes at an important time for the inhalation industry and IPAC-RS. As pressurized metered dose inhaler (pMDI) manufacturers prepare for the transition to next-generation propellants (NGPs) with lower global warming potential (GWP), close collaboration between industry and regulators will play an increasingly important role in maintaining patient access to essential medicines.

Throughout his career, Nick has helped guide complex regulatory strategies across global markets. At Kindeva, he leads the company’s global regulatory affairs function, supporting customers as they navigate evolving requirements for inhalation products while helping accelerate the development and commercialization of new therapies.

His election further strengthens Kindeva’s long-standing involvement in the inhalation community. As one of the pioneers of pMDI technology and a company leading the industry’s transition to NGPs, Kindeva continues to contribute technical and regulatory expertise to discussions shaping the future of inhaled drug products.

Commenting on his appointment, Nick said: “It is a privilege to be elected Vice Chair of the IPAC-RS Board of Directors. The inhalation industry is entering a period of significant scientific and regulatory evolution, particularly as we work together to enable the transition to next-generation propellants. I look forward to working alongside colleagues across the industry to support evidence-based decision-making and regulatory approaches that ultimately benefit patients around the world.”

Nick’s appointment reflects both his individual leadership and Kindeva’s continued commitment to advancing inhalation science, regulatory excellence and the future of pMDI development.